|
KAI Pharmaceuticals Buys Patents from Progen
Jul 03, 2009 (Close-Up Media via COMTEX) --
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced the acquisition of an extensive collection of issued and pending patents from Progen Pharmaceuticals, a globally focused biotechnology company.
KAI said the patents claim compositions and methods related to transporter molecules that can deliver compounds, including peptides such as those being developed in the KAI pipeline, across biological membranes and into cells. Terms of the agreement were not disclosed.
"This is important technology to KAI, further strengthening our position as a leader in the field of peptide therapeutics," said Steven James, President and CEO of KAI. "We use rationally designed peptides to target individual protein kinase C (PKC) isozymes inside cells. Combining these small peptides with peptide transporter systems is the basis for the cellular delivery of our multiple clinical candidates. Our unique approach overcomes lack of specificity, the primary deficiency encountered in previous attempts to develop PKC-targeted therapeutics using conventional methods. Beyond PKC, there are a number of both intracellular and extracellular targets that are amenable to KAI's peptide-based R&D platform."
((Comments on this story may be sent to health@closeupmedia.com))
[ Back To TMCnet.com's Homepage ]
|